Janice Tiao, MD
Dermatology · Boston, MANPI 1093179533
Payments from drug & device makers
Across 22 payments — averaging $252.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$3K
- AbbVie$1K
- Novartis$281
- Bristol Myers Squibb$198
- Janssen Scientific Affairs, LLC$124
- Sanofi$119
- plus $292 from 4 others
What the payments were for
- Consulting fees$3,45062%
- Food & beverage$2,10938%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $3,450 |
| AbbVie(2 entities) | 10 | $1,095 |
| Novartis | 3 | $281 |
| Bristol Myers Squibb | 2 | $198 |
| Janssen Scientific Affairs, LLC | 1 | $124 |
| Sanofi | 1 | $119 |
| Mallinckrodt Enterprises LLC | 1 | $106 |
| Galderma Laboratories, L.p. | 1 | $99 |
| Almirall LLC | 1 | $57 |
| Amgen | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,559 in reported general payments places this provider in the 70th percentile of 552 dermatology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 12 | $232,284 |
| Tacrolimus | 35 | $4,907 |
| Clobetasol Propionate | 47 | $3,268 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 41 | $2,966 |
| Fluorouracil | 52 | $2,748 |
| Mycophenolate Mofetil | 14 | $1,636 |
| Ketoconazole | 91 | $1,628 |
| Triamcinolone Acetonide | 129 | $1,427 |
| Metronidazole | 25 | $1,248 |
| Fluocinolone AcetonideFluocinolone/Shower Cap | 19 | $946 |
| Fluocinonide | 25 | $884 |
| Hydroxychloroquine Sulfate | 27 | $722 |
| Clindamycin Phosphate | 19 | $585 |
| Doxycycline Monohydrate | 14 | $569 |
| Spironolactone | 19 | $561 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Boston
- Alexandra KimballBoston$3.7M
- Gideon SmithBoston$2.6M
- Tarannum JaleelBoston$1.3M
- Maria Beatrice AloraBoston$1.3M
- Martina PorterBoston$1.1M
- Arash MostaghimiBoston$1M
- Emmy GraberBoston$882K
- Ruth Ann VleugelsBoston$786K
- Maryanne SennaBoston$783K
- Gabriela CobosBoston$558K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.